Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA.

Organisations Organisation Aimmune Therapeutics Inc. (Nasdaq: AIMT)
  Group Aimmune Therapeutics (Group)
  Organisation 2 Nestlé Health Science S.A.
  Group Nestlé (Group)
Index term Index term Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19%
Person Person Dallas, Jayson (Aimmune Therapeutics 201806– CEO before Ultragenyx + Roche + Novartis + Pfizer + P&G Pharma)
     


   
Record changed: 2019-04-01

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

More documents for Aimmune Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top